Efficacy of intralesional bevacizumab injection in decreasing pterygium size

Cornea

Volumn 30, Issue 2, 2011, Pages 127-129

  Tafti, Mohammad Reza Fallah ^a   Khosravifard, Keivan ^a   Mohammadpour, Mehrdad ^a   Hashemian, Mohammad Naser ^a   Kiarudi, Mohammad Yaser ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

bevacizumab; pterygium; VEGF

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMAGE ANALYSIS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; PTERYGIUM; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVAL DISEASES; HEMORRHAGE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRALESIONAL; MIDDLE AGED; PHOTOGRAPHY; PTERYGIUM; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 78651378954     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181e16d67     Document Type: Article

References (22)

1. Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: A positive correlation. Br J Ophthalmol. 1984;68:343-346.
2. Taylor HR, West S, Muñoz B, et al. The long-term effects of visible light on the eye. Arch ophthalmol. 1992;110:99-104.
3. Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006;113:1102-1109.
4. Frucht-Pery J, Siganos CS, Ilsar M. Intraoperative application of topical mitomycin C for pterygium surgery. Ophthalmology. 1996;103:674-677.
5. Maldonado MJ, Cano-Parra J, Navea-Tejerina A, et al. Inefficacy of lowdose intraoperative fluorouracil in the treatment of primary pterygium [letter]. Arch Ophthalmol. 1995;113:1356-1357.
6. Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology. 2005;112:1023-1030.
7. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22:473-477.
8. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007;69: 925-927.
9. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 2004;25:581-611. (Pubitemid 39099316)
10. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.
11. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.
12. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
13. Hashemian MN, Zare MA, Rahimi F, et al. Deep intrastromal bevacizumab injection for management of corneal stromal vascularization following deep anterior lamellar keratoplasty. Cornea. 2010.
14. Maini R, Collison DJ, Maidment JM, et al. Pterygial derived fibroblasts express functionally active histamine and epidermal growth factor receptors. Exp Eye Res. 2002;74:237-244.
15. Jiménez B, Volpert OV. Mechanistic insights on the inhibition of tumor ngiogenesis. J Mol Med. 2001;78:663-672.
16. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
17. Awadein, A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
18. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28. (Pubitemid 351156952)
19. Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009;93:864-865.
20. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28:468-470.
21. Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea. 2009;28:103-104.
22. Leippi S, Grehn F, Geerling G. Antiangiogenic therapy for pterygium recurrence. Ophthalmologe. 2009;106:413-419.